I hereby certify that this correspondence is being transmitted via The Office Electronic Filing System (EFS) in accordance with 37 CFR 1.6(a)(4).

Date of Electronic (EFS) Transmission: December 21, 2011

Signature: /Laurie A. Phillips/ Name: Laurie A. Phillips

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Applicant(s):	Alan H. Auerbach	Conf. No.:	1597
Application No.:	13/034,340	Group Art:	1628
Filing Date:	February 24, 2011	Examiner:	San Ming R. Hui
Title:	Methods and Compositions for Treating Cancer		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

The Office has issued a two-way restriction requirement relating to the present invention. Applicants hereby elect the invention of Group I, represented by newly presented claims 37 *et seq*. This election is made without traverse.

Listing of Claims:

1-36. (Canceled).

37. (New) A method for the treatment of a prostate cancer in a human comprising administering to said human a therapeutically effective amount of abiraterone acetate or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of prednisone.

38. (New) The method of claim 37, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 50 mg/day to about 2000 mg/day.

39. (New) The method of claim 38, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is from about 500 mg/day to about 1500 mg/day.

40. (New) The method of claim 39, wherein the therapeutically effective amount of the abiraterone acetate or pharmaceutically acceptable salt thereof is about 1000 mg/day.

41. (New) The method of claim 37, wherein the therapeutically effective amount of the abiraterone acetate or a pharmaceutically acceptable salt thereof is administered in at

least one dosage form comprising about 250 mg of abiraterone acetate or a pharmaceutically acceptable salt thereof.

42. (New) The method of claim 37, wherein the therapeutically effective amount of the prednisone is from about 0.01 mg/day to about 500 mg/day.

43. (New) The method of claim 42, wherein the therapeutically effective amount of the prednisone is from about 10 mg/day to about 250 mg/day.

44. (New) The method of claim 44, wherein the therapeutically effective amount of the prednisone is about 10 mg/day.

45. (New) The method of claim 37, wherein the therapeutically effective amount of the prednisone is administered in at least one dosage form comprising about 5 mg of prednisone.

46. (New) The method of claim 37, comprising administering to said human about 500 mg/day to about 1500 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 0.01 mg/day to about 500 mg/day of prednisone.

47. (New) The method of claim 46, comprising administering to said human about 1000 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10 mg/day of prednisone.

48. (New) The method of claim 37, wherein said prostate cancer is refractory prostate cancer.

49. (New) The method of claim 48, wherein the refractory prostate cancer is not responding to at least one anti-cancer agent.

50. (New) The method of claim 49, wherein the at least one anti-cancer agent comprises a hormonal ablation agent, an anti-androgen agent, or an anti-neoplastic agent.

51. (New) The method of claim 50, wherein the hormonal ablation agent comprises deslorelin, leuprolide, goserelin, or triptorelin.

52. (New) The method of claim 50, wherein the anti-androgen agent comprises bicalutamide, flutamide, or nilutamide.

53. (New) The method of claim 50, wherein the anti-neoplastic agent comprises docetaxel.

54. (New) The method of claim 48, comprising administering to said human about 500 mg/day to about 1500 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 0.01 mg/day to about 500 mg/day of prednisone.

55. (New) The method of claim 54, comprising administering to said human about 1000 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10 mg/day of prednisone.

56. (New) The method of claim 53, comprising administering to said human about 1000 mg/day of abiraterone acetate or a pharmaceutically acceptable salt thereof and about 10 mg/day of prednisone.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.